<DOC>
	<DOCNO>NCT01340846</DOCNO>
	<brief_summary>GSK2118436 orally administer , potent selective small molecule BRAF inhibitor develop treatment BRAF mutation-positive tumor . This 4-part study ( 4 separate cohort subject ) design examine interaction potential GSK2118436 , either perpetrator ( i.e. , effect GSK2118436 warfarin ; Part A ) victim ( i.e. , effect drug GSK2118436 ; Part B : ketoconazole Part C : gemfibrozil ) , well evaluate single repeat dose pharmacokinetic parameter GSK2118436 ( Part D ) . A sufficient number subject screen obtain approximately 12 evaluable subject Part A , Part B , Part C Part D. Following completion study , subject may continue dose GSK2118436 roll-over study , Protocol BRF114144 .</brief_summary>
	<brief_title>A Pharmacokinetics Study Effects GSK2118436 Warfarin , Effects Ketoconazole Gemfibrozil GSK2118436 , Effects Repeat Doses GSK2118436 Subjects With BRAF Mutant Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Male female least 18 year age time sign informed consent form ; Capable give write informed consent , include compliance requirement restriction list consent form ; Body weight &gt; /= 45 kg body mass index &gt; /= 19 kg/m2 &lt; /= 35 kg/m2 ( inclusive ) ; Able swallow retain oral medication ; BRAF V600 mutationpositive tumor determine CLIAapproved laboratory equivalent ( local BRAF testing may subject subsequent verification centralize test ) ; Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 ; NOTE : Subjects performance status 2 enrol patient 's confinement bed inability carry work activity due solely cancerrelated pain , assess Investigator ; Women childbearing potential men reproductive potential must willing practice acceptable method birth control . Additionally , woman childbearing potential must negative serum pregnancy test within 14 day prior first dose study medication ; Must adequate organ function define follow value : Absolute neutrophil count ( ANC ) &gt; /=1.2 x 109/L Hemoglobin &gt; /= 9 g/dL Platelets &gt; /= 100 x 109/L Serum bilirubin &gt; /= 1.5 x Upper Limit Normal ( ULN ) AST ALT &gt; /= 2.5 x ULN ; &lt; 5 x ULN liver metastasis present ( approval GSK medical monitor ) Serum creatinine &gt; /= ULN calculate creatinine clearance &gt; /= 60 mL/min PT/INR partial thromboplastin time ( PTT ) &gt; /= 1.3 x ULN Left ventricular ejection fraction &gt; /= institutional low limit normal ECHO CYP2C9 genotype *1/*1 ( wildtype ) , *1/*2 *1/*3 ( Part A ) Currently receive cancer therapy ( e.g. , chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy ) within last three week ; chemotherapy regimens without delayed toxicity within last 2 week ; The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 28 day , 5 halflives twice duration biological effect investigational product ( whichever warrant data ) ; Current use prohibit medication herbal preparation require medication study ; Consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose study medication ; History sensitivity heparin heparininduced thrombocytopenia ; Any major surgery within last 4 week ; Unresolved toxicity great National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( NCI CTCAE v4.0 ) [ NCI , 2009 ] Grade 2 previous anticancer therapy except alopecia ; Presence active GI disease condition ( e.g. , small bowel large bowel resection ) interfere significantly absorption drug . If clarification need whether condition significantly affect absorption drug , contact GSK medical monitor ; A history know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence HBV clearance may enrol ) ; Presence invasive malignancy , primary diagnosis ; Parts B C : Subjects brain metastasis exclude brain metastasis either : Symptomatic Treated ( surgery , radiation therapy ) clinically radiographically stable one month local therapy , Asymptomatic untreated &gt; 1 cm long dimension Patients small ( â‰¤ 1 cm long dimension ) , asymptomatic brain metastasis need immediate local therapy enrol approval GSK medical monitor . Subjects stable dose corticosteroid one month , corticosteroid least two week enrol . Subjects must also enzymeinducing anticonvulsant four week ; Note : Any brain metastasis exclusionary Part A ( must exclude prior image ) ; Corrected QT ( QTcB ) interval &gt; /= 480 msec ; History acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting within past 24 week ; Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system ; abnormal cardiac valve morphology document ECHO ( subject minimal abnormality [ i.e. , mild regurgitation/stenosis ] enter study clarification need whether ECHO abnormality minimal , please contact GSK medical monitor ) ; history know cardiac arrhythmia ( except sinus arrythmias ) within past 24 week ; Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , excipients ( note : date know drug chemically related GSK2118436 approve FDA ) ; Uncontrolled medical condition ( e.g. , diabetes mellitus , hypertension , liver disease ) , psychological , familial , sociological , geographical condition permit compliance protocol ; unwillingness inability follow procedure require protocol ; Subjects know glucose 6 phosphate dehydrogenase ( G6PD ) deficiency ; Pregnant female determine positive hCG test screen prior dosing ; Lactating females actively breast feeding ; Subject mentally legally incapacitate ; Part A : Use warfarin exogenous Vitamin K ( dietary source ) within 30 day prior treatment study medication ; Part A : Subjects history GI bleeding , GI ulceration ; Part A : Subjects know history Protein C and/or Protein S deficiency , type coagulopathy ; Part A : Subjects require type anticoagulation , take Aspirin dos great 81 mg/day ; Part A : Subjects brain metastasis ; Part A : Any subject history regularly consumes large quantity food rich vitamin K exclude unless he/she restricts vitamin K intake least one week prior first dose warfarin . For study purpose , large quantity vitamin Kcontaining food define 10 portion per week following : kale , spinach , turnip green , cauliflower , chick pea , brussels sprout , green tea , liver , soybean oil soy protein product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>ketoconazole</keyword>
	<keyword>GSK2118436</keyword>
	<keyword>warfarin</keyword>
	<keyword>gemfibrozil</keyword>
	<keyword>oncology</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>BRAF</keyword>
	<keyword>BRAF positive tumor</keyword>
	<keyword>Drug Interactions</keyword>
</DOC>